Xenocor Raises $10M Series A to Revolutionize Minimally Invasive Surgery with Saberscope

Xenocor is thrilled to announce a successful funding milestone with a $10,000,000 raise dedicated to advancing its innovative approach in minimally invasive surgery. Based in Salt Lake City, UT, Xenocor is a privately held corporation focused on transforming the surgical landscape by solving long-standing challenges in the operating room. The company’s pioneering Saberscope platform—a single-use, fog-free, articulating laparoscopic system—promises to enhance precision and visibility during surgical procedures, ultimately improving patient outcomes and streamlining hospital workflows. This substantial investment will fuel further research and development, accelerate manufacturing capabilities, and expand market reach, ensuring that the Saberscope technology becomes widely adopted across clinical settings. The new funds will not only drive product improvements and quality assurance but also support a strategic scale-up initiative designed to meet the growing global demand for minimally invasive surgical solutions. By eliminating common issues such as fogging and limited maneuverability in traditional laparoscopic devices, Xenocor is poised to deliver a more reliable and efficient tool for surgeons, reducing the risks and complexities inherent in surgical procedures. This investment underscores the confidence of investors in Xenocor’s vision and its potential to make a significant impact on healthcare delivery. As the company continues to push the boundaries of technological innovation, healthcare providers can look forward to a future where surgical procedures are safer, easier, and more effective. To learn more about Xenocor’s revolutionary approach and the Saberscope platform, visit www.saberscope.com/resources.